# 04_QA_REPORT.md

# Quality Assurance Report

---

# Identity

| Field | Value |
|-------|-------|
| QA Report ID | QA-PP-0234 |
| Population Package | PP-0234 |
| Title | Germline Genetic Testing |
| Version | 1.0.0 |
| Review Status | PASS |

---

# Layer 1 — Content QA

| Criterion | Result |
|-----------|--------|
| Single educational question | PASS |
| Scope respected | PASS |
| Complete coverage | PASS |
| Internal consistency | PASS |
| Logical organization | PASS |
| Knowledge blocks complete | PASS |
| Affected individuals covered | PASS |
| Unaffected individuals covered | PASS |
| Personal/family history covered | PASS |
| Gastric-cancer context covered | PASS |
| Testing approaches covered | PASS |
| Pretest process covered | PASS |
| Result categories covered | PASS |
| VUS explained | PASS |
| Negative result limitations covered | PASS |
| Unexpected findings covered | PASS |
| Family implications covered | PASS |
| Confirmatory germline testing covered | PASS |
| No overlap with downstream packages | PASS |

---

# Layer 2 — Clinical QA

| Criterion | Result |
|-----------|--------|
| Scientifically accurate | PASS |
| Consistent with NCI gastric-cancer genetics | PASS |
| Consistent with NCI hereditary cancer risk assessment | PASS |
| Consistent with NCI HDGC framework | PASS |
| Consistent with ESMO/ASCO framework | PASS |
| Consistent with NCCN gastric-cancer context | PASS |
| Appropriate germline vs somatic distinction | PASS |
| Appropriate explanation of hereditary risk | PASS |
| Appropriate explanation of personal/family history | PASS |
| Appropriate explanation of test categories | PASS |
| Appropriate VUS boundary | PASS |
| Appropriate negative-test boundary | PASS |
| Appropriate unexpected-finding boundary | PASS |
| Appropriate family implication boundary | PASS |
| Appropriate tumor-to-germline confirmation boundary | PASS |
| No unsupported treatment recommendation | PASS |
| No unsafe medical advice | PASS |

---

# Layer 3 — Educational QA

| Criterion | Result |
|-----------|--------|
| Plain language | PASS |
| Patient-friendly wording | PASS |
| Learning objectives satisfied | PASS |
| Medical terminology explained | PASS |
| Knowledge blocks follow clinical logic | PASS |
| Patient explanation included | PASS |
| Clinical importance included | PASS |
| Key concepts included | PASS |
| Common misconceptions addressed | PASS |
| Key messages included | PASS |
| Appropriate uncertainty communicated | PASS |
| Family implications explained without overreach | PASS |
| Testing limitations explained | PASS |

---

# Layer 4 — Governance QA

| Criterion | Result |
|-----------|--------|
| CKO completed | PASS |
| Knowledge Passport completed | PASS |
| Evidence Package completed | PASS |
| QA Report completed | PASS |
| Evidence traceability complete | PASS |
| Scope boundary defined | PASS |
| Knowledge Graph complete | PASS |
| Prerequisites defined | PASS |
| Related packages defined | PASS |
| Next package defined | PASS |
| Versioning complete | PASS |
| Repository structure compliant | PASS |
| Gold Specification alignment | PASS |
| Four-artifact package complete | PASS |

---

# Clinical Safety Review

| Item | Result |
|------|--------|
| No individualized testing recommendation | PASS |
| No individualized surveillance recommendation | PASS |
| No treatment recommendation | PASS |
| No gene-specific management algorithm | PASS |
| No detailed HDGC criteria presented as universal criteria | PASS |
| No ACMG classification methodology presented | PASS |
| VUS not treated as pathogenic | PASS |
| Negative result not presented as complete exclusion of risk | PASS |
| Tumor finding not automatically labeled germline | PASS |
| Confirmatory germline testing appropriately framed | PASS |
| Family implications appropriately contextualized | PASS |
| Cascade testing workflow excluded | PASS |

---

# Educational Boundary Review

The Population Package remains within the locked atomic scope.

## Included

- What germline testing is.
- Germline vs somatic testing.
- Why it matters in gastric cancer.
- Who may be considered.
- Personal/family history.
- Single-gene vs multigene testing.
- Pretest education/informed consent at conceptual level.
- Pathogenic/likely pathogenic, VUS, and negative results.
- Unexpected findings.
- Family implications.
- Confirmatory germline testing after suspicious tumor findings.
- Limitations.

## Excluded

- Detailed genetic counseling.
- Detailed HDGC criteria.
- CDH1 management.
- CTNNA1 management.
- ACMG/AMP classification.
- Detailed sequencing methodology.
- Cascade testing workflow.
- Treatment algorithms.

The **Atomic Knowledge Principle** has been preserved.

---

# Evidence Traceability Review

The principal clinical claims are traceable to the approved project sources.

## 1. Gastric-cancer hereditary context

NCI's Genetics of Gastric Cancer PDQ identifies hereditary syndromes and cancer-predisposition genes relevant to gastric cancer and reports germline pathogenic-variant findings from multigene-panel and paired sequencing studies. fileciteturn62file6

## 2. Personal and family history / testing process

NCI's Cancer Genetics Risk Assessment and Counseling PDQ describes hereditary cancer risk assessment, testing approaches, pretest education/counseling, informed consent, and family implications. fileciteturn62file12

## 3. Germline testing and inherited conditions

The ESMO/ASCO Global Curriculum includes genetic and genomic testing within oncology education and recognizes evaluation for inherited conditions and the clinical relevance of possible germline findings identified through molecular profiling. fileciteturn61file17

## 4. Current gastric-cancer clinical context

NCCN Gastric Cancer Version 2.2026 includes a dedicated section on genetic risk assessment for gastric cancer and integrates molecular/biomarker assessment into the clinical pathway. fileciteturn61file18

---

# Package Completeness Review

| Required Artifact | Status |
|-------------------|--------|
| 01_CKO.md | COMPLETE |
| 02_Knowledge_Passport.md | COMPLETE |
| 03_PRIMARY_EVIDENCE_PACKAGE.md | COMPLETE |
| 04_QA_REPORT.md | COMPLETE |

---

# Reviewer Notes

PP-0234 is positioned as the **foundational germline-testing process node** rather than a disease-specific HDGC package or a technical sequencing package.

The central architecture is:

**who may need testing**
→ **why testing is considered**
→ **what happens before testing**
→ **what kinds of results can occur**
→ **what those results may mean**
→ **what may matter for relatives**
→ **when tumor findings require germline confirmation**

The package deliberately maintains the following boundaries:

- Germline testing ≠ genetic counseling.
- Germline testing ≠ variant interpretation.
- Germline testing ≠ HDGC management.
- Germline testing ≠ cascade testing.
- Germline testing ≠ somatic tumor testing.

This prevents duplication with PP-0106, PP-0107, PP-0110, and downstream hereditary-cancer packages.

---

# Final Quality Decision

## PASS

PP-0234 satisfies the locked **Gold Population Package Specification v1.0**.

Approved as the official Population Package for:

> **PP-0234 — Germline Genetic Testing**

Repository Status: **Ready**.

---

# Revision History

| Version | Date | Summary |
|----------|------|---------|
| 1.0.0 | 2026-08-08 | Revised Gold Release — expanded to match approved Gold package depth and locked PP-0234 scope |
